News - Metsera
Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape.
Metsera Reports Highly Competitive Results from Ongoing Trial …
NEW YORK, September 24, 2024 -- (BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today...
Metsera
Metsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases.
Metsera Launches to Lead the Next Generation of Medicines for …
2024年4月18日 · Founded by Population Health Partners and ARCH Venture Partners and led by former executives of The Medicines Company, Metsera is rapidly advancing a broad portfolio of oral and injectable ...
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
2024年9月24日 · Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body weight compared to baseline at 36 days. While the biotech has yet to...
Amneal and Metsera Announce Strategic Collaboration to …
2024年10月1日 · Metsera is advancing a portfolio of next-generation therapies for obesity and metabolic diseases, including ultra-long acting injectable and oral nutrient stimulated hormone (NuSH) analogs and...
Arch-backed obesity biotech launches with $290M - Fierce Biotech
2024年4月18日 · Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. “It's an almost...
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
2024年9月24日 · Obesity drug startup Metsera on Tuesday reported its first clinical data since launching in April with $290 million in venture funding. The data come from a Phase 1 trial of a drug, MET-097, that’s designed to have longer-lasting effects than injectable GLP-1 therapies like Novo Nordisk’s Wegovy.
GLP-1 start-up Metsera launches with $290 million
2024年4月18日 · Metsera is advancing a suite of peptide and peptide-antibody conjugate drugs for weight loss and other indications, all based on GLP-1 agonists.
Metsera comes out of stealth with $290 million for obesity drugs
2024年4月18日 · Metsera came out of stealth mode Thursday with $290 million in seed and Series A financing. ARCH and Population Health Partners, which launched in 2020 and has several veterans from Pfizer and...